CardiologyOnline.net

Cardiology Xagena

Myocardial infarction patients without heart failure derive no benefit from the addition of mineralocorticoid receptor antagonists ( MRA; antimineralocorticoids ), to standard therapy, results of the ...


The immunosuppressant drug Cyclosporine did not improve clinical outcomes compared to placebo in patients receiving percutaneous coronary intervention ( PCI ) for the more severe form of heart attack ...


In heart failure patients with diabetes mellitus and/or chronic kidney disease, a new, non-steroidal mineralocorticoid receptor antagonist ( MRA ) called Finerenone was no more effective than the curr ...


Patients with type-2 diabetes and cardiovascular disease can safely take the antihyperglycemic drug Sitagliptin ( Januvia ) without an increased risk of cardiovascular complications, even if they have ...


The combination drug Valsartan / Sacubitril known as LCZ696 ( Entresto ) significantly reduced aortic systolic blood pressure and pulse pressure compared to the standard angiotensin receptor blocker ( ...


The 2015 ESC Guidelines on the diagnosis and management of pericardial diseases are published in European Heart Journal. Previous ESC Guidelines on this topic were published in 2004. The pericardiu ...


The ESC Guidelines for the management of infective endocarditis are published in European Heart Journal, For the first time, the guidelines recommend that an endocarditis team operating in a referenc ...


The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension are published in the European Heart Journal and the European Respiratory Journal. The document was written joint ...


The FDA ( Food and Drug Administration ) is alerting health care providers, patients, and caregivers about serious adverse events associated with implantable left ventricular assist devices ( LVADs ). ...


Fine particulate matter air pollution ( PM2.5 ) and extreme temperatures have both been associated with alterations in blood pressure ( BP ). However, few studies have evaluated their joint haemodynam ...


Postoperative atrial fibrillation ( POAF ) is a common complication after cardiac surgery and predicts increased morbidity and mortality. Identification of patients at high risk of postoperative atri ...


Cardiac device wearers should keep a safe distance from smartphones to avoid unwanted painful shocks or pauses in function, reveals research presented at EHRA EUROPACE – CARDIOSTIM 2015 by Carsten Len ...


The European Society of Cardiology ( ESC ) has recommended uninterrupted anticoagulation with vitamin K antagonists during ablation and device implantation in a position paper presented at EHRA EUROPA ...


While menopause is commonly considered a risk factor for heart disease, menopausal women had a lower risk of dying from myocardial infarction than men; however, this difference was less pronounced amo ...


A study has compared efficacy and safety among novel oral anticoagulants ( NOACs ), which have not been directly compared in randomized control trials to date. Investigators performed network meta- ...


A study has analysed the treatment and control of dyslipidaemia in patients at high and very high cardiovascular risk being treated for the primary prevention of cardiovascular disease ( CVD ) in Euro ...


The PARADIGM-HF ( Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure ) trial has demonstrated that a new angiotensin receptor antagonist - ...


Little is known about Ivabradine ( US: Corlanor; Europe: Corlentor, Procoralan ) in cardiac rehabilitation in patients with coronary artery bypass graft ( CABG ). In this prospective, randomized st ...


Cumulative blood pressure ( BP ) exposure may adversely influence myocardial function, predisposing individuals to heart failure later in life. A study sought to investigate how cumulative exposure ...


Studies of patients presenting for catheter ablation suggest that premature ventricular contractions ( PVCs ) are a modifiable risk factor for congestive heart failure ( CHF ). The relationship amon ...


Researchers have examined the relationship between different degrees of QRS prolongation and different QRS morphologies and clinical outcomes in patients with heart failure, reduced ejection fraction ...


Patients with acute heart failure ( AHF ) commonly have multiple co-morbidities, and some of these patients die in the hospital from causes other than aggravated heart failure. However, limited info ...


In the ENGAGE AF-TIMI 48 trial, the higher-dose Edoxaban ( HDE; Lixiana, Savaysa ) regimen had a similar incidence of ischaemic stroke compared with Warfarin ( Coumadin ), whereas a higher incidence w ...


In patients with persistent atrial fibrillation ( AF ), the sinus rhythm ( SR ) can be restored by direct current cardioversion ( DCC ), although the recurrence of atrial fibrillation after successful ...


Transcatheter aortic valve implantation ( TAVI ) is a therapeutic treatment for patients with severe aortic stenosis ( AS ) at high surgical risk. Although the procedure is associated with a reducti ...


Emerging clinical evidence demonstrates high prevalence of QTc prolongation and complex ventricular arrhythmias in patients with anti-Ro antibody ( anti-Ro Ab ) positive autoimmune diseases. Resea ...


Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk ...


Recent trials have shown a reduction in the risk of major adverse cardiac events ( MACE ) with Simvastatin and Ezetimibe ( Vytorin ) therapy in patients with acute coronary syndrome. The potential be ...


The effect of LCZ696 on blood pressure was evaluated in patients with heart failure with preserved ejection fraction ( HFpEF ) in the PARAMOUNT ( Prospective comparison of ARNI with ARB on Management ...


Patients with a high-risk Paclitaxel drug-eluting stent who were given the shorter-acting antiplatelet drug Cilostazol ( Pletal ) prior to a surgical procedure safely transitioned off of dual antiplat ...


A 8-week, multicenter, open-label study has assessed the safety and efficacy of LCZ696 ( Entresto ), a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension ...


Heart failure and dementia frequently coexist, but little is known about their types, relationships to each other and prognosis. The aims of this study were to (i) describe patients with heart failu ...


Catheter ablation of atrial fibrillation is an established therapy for symptomatic patients. The long-term efficacy and impact of catheter ablation among patients with severe systolic heart failure re ...


Sudden cardiac death ( SCD ) is a leading cause of mortality in patients with cardiomyopathy. Although angiotensin-converting enzyme inhibitors ( ACEi ) and angiotensin receptor blockers ( ARBs; sarta ...


The results from two analyses of the GLORIA-AF Registry Program examining the use of antithrombotic treatment to reduce the risk of stroke for patients with non-valvular atrial fibrillation ( NVAF ) w ...


The recent availability of Dabigatran ( Pradaxa ), a novel oral anticoagulant, provided a new treatment option for stroke prevention in atrial fibrillation beyond Warfarin ( Coumadin ), the main thera ...


The new oral anticoagulants ( NOACs ) Dabigatran etexilate ( Pradaxa ), Rivaroxaban ( Xarelto ), and Apixaban ( Eliquis ) show similar efficacy for stroke prevention in patients with atrial fibrillati ...


Atrial fibrillation is the most frequent sustained arrhythmia. Atrial fibrillation frequently recurs after restoration of normal sinus rhythm. Antiarrhythmic drugs have been widely used to prevent r ...


Two separate clinical trials were presented as a part of ACC.15, and looked at strategies to reduce major bleeding and mortality in patients with acute coronary syndrome ( ACS ). Both trials are part ...


Patients taking Digoxin ( Lanoxin ) to control atrial fibrillation face a 27% greater risk of dying than atrial fibrillation patients who are not taking digoxin, according to an analysis of 19 studies ...


The FDA ( Food and Drug Administration ) has expanded the approved use of the CoreValve System to treat certain patients who have previously had a tissue aortic valve replacement and are in need of a ...


The important factor for efficacy and safety for patients with atrial fibrillation undergoing electrical cardioversion ( ECV ) is appropriate use of oral anticoagulant ( OAC ) therapy. Dabigatran ( ...


Current guidelines do not explicitly recommend statin use in heart failure ( HF ). Relatively low numbers of atherothrombotic events among patients with heart failure, in the context of their elevated ...


New detailed data from the phase 3 YUKAWA-2 study evaluating Evolocumab ( Repatha ), a novel investigational cholesterol-lowering medication, in Japanese patients with high cardiovascular risk and hig ...


New oral anticoagulants for stroke prevention in atrial fibrillation were developed to be given in fixed doses without the need for the routine monitoring that has hindered usage and acceptance of vit ...


Researchers have examined the influence of catheter ablation ( CA ) and peri-procedural anticoagulation regimen on trajectory of migraine in atrial fibrillation patients with or without migraine-histo ...


Thiazide diuretics are recommended as first-line therapy for hypertension and are among the most commonly prescribed drugs worldwide. According to their molecular structure, thiazide diuretics can b ...


The FDA ( Food and Drug Administration ) has approved the ResQCPR System, a system of two devices for first responders to use while performing cardiopulmonary resuscitation ( CPR ) on people with card ...


A study has examined the efficacy and bleeding outcomes of Cangrelor ( Kengrexal ) in patients in the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects ...


Intravenous ( IV ) Morphine has been shown to be independently associated with adverse clinical outcome in patients with non-STEMI. Currently, there are no data on the association of IV Morphine and r ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati